Oct. 25, 2018
Amgen announced on Wednesday, Oct. 24 it is making evolocumab available at a reduced list price in an effort to improve affordability and access for patients.
The announcement represents positive news for patients at risk for cardiovascular events.
Key outcomes from Amgen’s FOURIER trial, revealed in March 2017, revealed evolocumab significantly reduced the risk of cardiovascular events and were supported by long-term safety data.
JACKSONVILLE, Fla. — The National Lipid Association announced on Friday the recipients of its 2018-19 Junior Faculty Research Awards for Clinical Science and Basic Science.